Skip to main content
. 2023 Oct 16;29(11):2919–2928. doi: 10.1038/s41591-023-02603-1

Extended Data Fig. 1. Resmetirom-mediated reduction in hepatic fat.

Extended Data Fig. 1

Least squares (LS) mean change from baseline (95% confidence interval (CI)) in hepatic fat (measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF)) at Week 52 in patient subgroups of the double-blind 100 mg resmetirom and double-blind 80 mg resmetirom arms. Marker shows median. High SHBG, population with ≥120% increase from baseline in SHBG.